Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 4 Results of cost-effectiveness by trial (1-year) and lifetime time horizons. Mean and 95 % CI presented

From: Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods

 

Standard

FFR

Incremental

ICER

Costs (£)

QALYs

Costs (£)

QALYs

Costs (£)

QALYs

(£/QALY)

Trial

7574 (6963–8443)

0.80 (0.76–0.84)

7686 (7141–8482)

0.82 (0.79–0.85)

112 (−129 to 357)

0.01 (−0.03 to 0.06)

7516

Lifetime

10,954 (9482–12,614)

6.30 (5.07–7.23)

11,087 (9652–12,699)

6.33 (5.09–7.25)

133 (−199 to 499)

0.03 (−0.21 to 0.28)

4290

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us